Proteomic Analysis of Gouty Arthritis Lesions Across Disease Stages

A proteomics study of 200 gouty arthritis patients, identifying 810 differentially expressed proteins between chronic and acute disease phases. The research, by Niqin Xiao, validates three ferroptosis-related proteins (GPX4, FTH1, ALOX15) as potential biomarkers for disease staging and treatment strategies.

Use Cases

• Analyze the 810 differentially expressed proteins, including 548 upregulated and 262 downregulated, to identify key biological pathways in gouty arthritis progression.
• Validate the differential expression of specific proteins like GPX4, FTH1, and ALOX15 across chronic (tophi) and acute (effusion) patient groups.
• Apply GO and KEGG pathway enrichment analysis to the identified protein set to investigate associations with processes like ferroptosis.
• Compare proteomic profiles from the chronic phase group (n=100) and acute phase group (n=100) to discover stage-specific inflammatory signatures.

Strengths

• Dataset is derived from a study of 200 gouty arthritis patients, providing a substantial clinical sample size.
• Proteomic analysis identified a specific set of 810 differentially expressed proteins with clear up/down regulation counts.
• Findings are validated via Western blot for three key proteins (GPX4, FTH1, ALOX15), adding experimental confirmation.
• Data is openly shared under a CC BY 4.0 license, facilitating reuse and secondary analysis.

Limitations

• The core proteomic analysis was performed on a small subset (5 cases per group) of the total 200-patient cohort.
• Dataset is a static 1.7 MB file from a specific research project with no stated update frequency.
• Clinical and demographic details for the patient cohorts are not described in the available metadata.

Provenance

Source

Figshare, authored by Niqin Xiao.

Collection Method

Cross-sectional clinical study with local lesion proteomics and Western blot validation.

Time Range

null

Freshness

null

Geography

null